These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31490989)

  • 1. Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review.
    van Schoonhoven AV; Gout-Zwart JJ; de Vries MJS; van Asselt ADI; Dvortsin E; Vemer P; van Boven JFM; Postma MJ
    PLoS One; 2019; 14(9):e0221856. PubMed ID: 31490989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands.
    van Schoonhoven AV; Schöttler MH; Serné EH; Schrömbges PPG; Postma MJ; Boersma C
    J Med Econ; 2023; 26(1):547-553. PubMed ID: 36987694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling.
    Brennan VK; Colosia AD; Copley-Merriman C; Mauskopf J; Hass B; Palencia R
    J Med Econ; 2014 Jul; 17(7):469-80. PubMed ID: 24773097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
    Nguyen C; Luthra R; Kuti E; Willey VJ
    Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular event incidence and cost in type 2 diabetes mellitus: a Medicare claims-based actuarial analysis.
    Fitch K; Engel T; Sander S; Kuti E; Blumen H
    Curr Med Res Opin; 2017 Oct; 33(10):1795-1801. PubMed ID: 28641023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review.
    Brennan VK; Mauskopf J; Colosia AD; Copley-Merriman C; Hass B; Palencia R
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):111-23. PubMed ID: 25555462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review.
    Einarson TR; Acs A; Ludwig C; Panton UH
    Value Health; 2018 Jul; 21(7):881-890. PubMed ID: 30005761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
    Hemmingsen B; Gimenez-Perez G; Mauricio D; Roqué I Figuls M; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003054. PubMed ID: 29205264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of interventions to reduce overnutrition on healthcare costs related to obesity and type 2 diabetes: a systematic review.
    Olm M; Stark RG; Beck N; Röger C; Leidl R
    Nutr Rev; 2020 May; 78(5):412-435. PubMed ID: 31769843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of managing Type 2 diabetes mellitus: Analysis from a Teaching Hospital in Malaysia.
    Ismail A; Suddin LS; Sulong S; Ahmed Z; Kamaruddin NA; Sukor N
    Indian J Public Health; 2017; 61(4):243-247. PubMed ID: 29219128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular event costs in patients with Type 2 diabetes mellitus.
    Johnston SS; Sheehan JJ; Shah M; Cappell K; Princic N; Smith D; Kalsekar I
    J Med Econ; 2015; 18(12):1032-40. PubMed ID: 26189723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital costs of ischemic stroke and TIA in the Netherlands.
    Buisman LR; Tan SS; Nederkoorn PJ; Koudstaal PJ; Redekop WK
    Neurology; 2015 Jun; 84(22):2208-15. PubMed ID: 25934858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands.
    de Groot S; Enters-Weijnen CF; Geelhoed-Duijvestijn PH; Kanters TA
    BMJ Open; 2018 Mar; 8(3):e019864. PubMed ID: 29581204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.